When Richard, one of our founders, was the Chief Executive Officer of OneWorld Health, he noticed something extraordinary.
At OneWorld Health, a Gates Foundation-funded nonprofit that develops drugs for poverty-stricken patients, Richard was developing drugs to fight diseases like malaria and cholera. As he searched high and low for new drugs to help patients in the poorest parts of Africa and Asia, he realized that drugs for neglected diseases often come from the veterinary field.
Richard had stumbled onto something that few physicians today know, but was common knowledge two centuries ago. The fields of animal medicine and human medicine are brother and sister. Drugs that work for humans almost always work for animals, and drugs that work in animals virtually always work in humans. And diseases in animals, like Alzheimer’s disease, asthma, lupus, congestive heart failure, Crohn’s diseases, and cancer, are twins to those in people.
But despite this, there is a gap between the two fields. Veterinarians and physicians rarely talk to one another. Realizing this, Richard thought that perhaps, there might be hidden opportunities, drugs from the human pharmaceuticals field that might be developed for companion animals, drugs formerly forgotten or abandoned that could revolutionize care for animals.
He found that there were.
As he looked further, he also discovered that veterinary market is just past a major tipping point. He found that it has recently become a vibrant, highly attractive field with low competition. In many ways, it echoes the human pharmaceutical field 30 or 40 years ago. That was the dawn of the golden age of pharmaceuticals when opportunity and profit were plentiful, reimbursement was simple, commercialization was affordable, and generics were obscure.
There are drugs, knowledge, and technology that exist on one side of the chasm between human and animal medicine that could transform medicine on the other side. In particular, biologics such as monoclonal antibodies, which have revolutionized human medicine, is now starting to transform veterinary medicine. KindredBio was founded to capitalize on this extraordinary opportunity and to carry the best medicines and technologies across this gap.
And already, KindredBio has received approval of two drugs, and is poised to bring several other very promising drugs to market. We have built a world-class protein engineering and manufacturing organizations, and have established ourselves as a leading innovative biotech in the veterinary field.
At the interface between human and animal medicine, there lies great opportunity. We believe that KindredBio has embarked on an extraordinary journey, with great benefits for animals and with attractive rewards for our investors.